Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Interest & Investment Income: 2020-2025

Historic Interest & Investment Income for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to $3.3 million.

  • Lyell Immunopharma's Interest & Investment Income fell 45.25% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year decrease of 41.58%. This contributed to the annual value of $24.1 million for FY2024, which is 2.62% up from last year.
  • As of Q3 2025, Lyell Immunopharma's Interest & Investment Income stood at $3.3 million, which was down 0.31% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Interest & Investment Income peaked at $7.1 million during Q4 2023, and registered a low of $218,000 during Q2 2021.
  • For the 3-year period, Lyell Immunopharma's Interest & Investment Income averaged around $5.3 million, with its median value being $5.3 million (2023).
  • Per our database at Business Quant, Lyell Immunopharma's Interest & Investment Income crashed by 90.69% in 2021 and then spiked by 1,032.75% in 2023.
  • Lyell Immunopharma's Interest & Investment Income (Quarterly) stood at $323,000 in 2021, then soared by 969.04% to $3.5 million in 2022, then skyrocketed by 105.15% to $7.1 million in 2023, then tumbled by 30.55% to $4.9 million in 2024, then plummeted by 45.25% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $3.3 million for Q2 2025, and $3.9 million during Q1 2025.